
USFDAJun 15, 2026, 04:12 PM
Inhibrx BLA for Ozekibart Accepted by FDA; PDUFA April 14, 2027
AI Summary
Inhibrx Biosciences announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) for ozekibart (INBRX-109). The BLA seeks approval for the treatment of patients with unresectable or metastatic conventional chondrosarcoma, a condition with no currently approved therapies. The FDA has not identified any filing review issues and has set a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027. The application is supported by positive results from the ChonDRAgon study, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival.
Key Highlights
- FDA accepted Biologics License Application (BLA) for ozekibart (INBRX-109) for conventional chondrosarcoma.
- PDUFA goal date is set for April 14, 2027, with no filing review issues identified by the FDA.
- Ozekibart would be the first FDA-approved treatment for unresectable or metastatic conventional chondrosarcoma.
- ChonDRAgon study showed ozekibart achieved a 52% reduction in disease progression or death risk vs. placebo.
- Median progression-free survival (PFS) more than doubled to 5.52 months vs. 2.66 months for placebo.
- Disease control rate was 54% for ozekibart compared to 27.5% for placebo.
- Ozekibart received Fast Track designation in January 2021 and Orphan Drug designation in November 2021.
Price Impact
More from INBX